A review of MRI appearances of lipiodol in conventional tace (cTACE) treated hepatocellular carcinomas | [Journal of Ayub Medical College • 2023]

Author(s):

1. Zahid Amin Khan: Department of diagnostic and interventional Radiology, Shifa International Hospital,Islamabad-,Pakistan

2. Atif Iqbal Rana: Department of diagnostic and interventional Radiology, Shifa International Hospital,Islamabad-,Pakistan

3. Maria Rauf: Department of diagnostic and interventional Radiology, Shifa International Hospital,Islamabad-,Pakistan

4. Jamshaid Anwar: Department of diagnostic and interventional Radiology, Shifa International Hospital,Islamabad-,Pakistan

5. Haider Ali: Department of diagnostic and interventional Radiology, Shifa International Hospital,Islamabad-,Pakistan

6. Ahmad Ammar Afzal: Department of diagnostic and interventional Radiology, Shifa International Hospital,Islamabad-,Pakistan

Abstract:

Background: The global burden of patients affected by chronic liver disease (CLD) has shown a steady rise over the last few decades and is now considered the 11th most frequent cause of death globally. In addition, as the world population is facing increased obesity rates coupled with alcohol consumption, these rates are predicted to continue to rise. The Objective was to assess the appearance of Lipiodol retention upon different MRI sequences with a special focus on non-contrast sequences. Lipiodol Transarterial chemoembolization (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC) without vascular invasion. However, data regarding Lipiodol TACE imaging via MRI is limited and results are not familiar to radiologists for regular assessment of treatment response. Methods: After IRB and EC approval, we included all those patients who underwent TACE treatment with Lipiodol and chemotherapeutic agent; having both 4-6-week post-treatment CT and MRI imaging. This criterion was fulfilled by a total of 25 patients. Only lipiodol-containing areas within the lesion were noted for signal intensities on all MRI sequences and labelled as hyperintense, isointense, hypointense and mixed intensity. Data was entered and analyzed by SPSS v27. Frequencies and percentages were calculated for qualitative data. Results: The most sensitive sequence in detecting Lipiodol retention was Fat suppressed T1 imaging sequence, with low signal intensity seen on T1 weighted fat-suppressed sequences in up to 76% of lesions. While on non-fat suppressed T1 weighted images, 60% of Lipiodol retention areas appeared hyperintense. 52% of lesions showed a hypointense appearance on the T2 weighted sequence. A much more variable appearance was seen in Diffusion-weighted imaging sequences demanding cautious interpretation. MR patterns were clearer in patients having more than 50% lipiodol retention on CT and lesion size more than 2 cm. Conclusion: While MRI is deemed as a reliable and most useful imaging modality for assessing HCC's following lipiodol TACE it requires cautious interpretation with knowledge of variable signal appearance seen on different imaging sequences.

Page(s): 740-745

DOI: 10.55519/JAMC-S4-11966

Published: Journal: Journal of Ayub Medical College, Volume: 35, Issue: 4(S), Year: 2023

Keywords:

Magnetic Resonance Imaging , hepatocellular carcinoma , Computed tomography , Lipiodol , Retention pattern

References:

[1] Cheemerla S,Balakrishnan M. Global .2021 .Epidemiology of Chronic Liver Disease. Clin Liver Dis, 17(5) : 365-70.

[2] Renne SL,Sarcognato S,Sacchi D,Guido M,Roncalli M,Terracciano L .2021 .Hepatocellular carcinoma: a clinical and pathological overview. Pathologica, 113(3) : 203-17.

[3] Rahib L,Smith BD,Aizenberg R,Rosenzweig AB,Fleshman JM,Matrisian LM .2014 .Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 74(14) : 2913-21.

[4] Reig M,Forner A,Rimola J,Ferrer-Fábrega J,Burrel M,Garcia-Criado A .2022 .BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. J Hepatol, 73(3) : 681-93.

[5] Galle PR,Forner A,Llovet JM,Mazzaferro V,Piscaglia F,Raoul JL .2018 .EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 69 : 182-236.

[6] .2016 .. Cardiovasc Intervent Radiol, 39(3) : 334-43.

[7] Miszczuk MA,Chapiro J,Geschwind JFH,Thakur V,Nezami N,Laage-Gaupp F .2020 .Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol, 13(3) : 100742.

[8] Lee MJ,Kim MJ,Baek SY .2016 .MRI Findings of Lipiodol Uptake in Hepatocellular Carcinomas: A Focus on Signal Intensity. Ewha Med J, 39(4) : 110-7.

[9] Luedemann WM,Geisel D,Gebauer B,Schnapauff D,Chapiro J,Wieners G .2020 .Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR. CT? Eur Radiol, 30(3) : 1601-8.

[10] Hussein RS,Tantawy W,Abbas YA .2019 .MRI assessment of hepatocellular carcinoma after locoregional therapy. Insight Imaging, 10(8) : 1-16.

[11] Saleh TY,Bahig S,Shebrya N,Ahmed AY .2019 .Value of dynamic and DWI MRI in evaluation of HCC viability after TACE via LI-RADS v2018 diagnostic algorithm. Egypt J Radiol Nucl Med, 50(1) : 1-11.

[12] Feng L,Liu F,Soultanidis G,Liu C,Benkert T,Block KT .2021 .Magnetization-prepared GRASP MRI for rapid 3D T1 mapping and fat/water-separated T1 mapping. Magn Reson Med, 86(1) : 97-114.

[13] Biousse V,Newman NJ,Hunter SB,Hudgins PA .2003 .Diffusion weighted imaging in radiation necrosis. J Neurol Neurosurg Psychiatry, 74(3) : 382-4.

[14] Subtraction MRI .2016 .versus diffusion weighted imaging: Which is more accurate in assessment of hepatocellular carcinoma after Trans Arterial Chemoembolization (TACE)?. Egypt J Radiol Nucl Med, 47(4) : 1251-64.

[15] A Metwally LI,Eldin Mahmoud B,Yehia M. .2019 .The value of dynamic subtraction MRI technique in the assessment of treatment response of hepatocellular carcinoma to transcatheter arterial chemoembolization. Egypt J Radiol Nucl Med, 50 : 1-13.

[16] Kloeckner R,Otto G,Biesterfeld S,Oberholzer K,Dueber C .2010 .MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol, 33(3) : 532-40.

[17] .2023 .. 2023 Revised: December, 21 : .

Citations

Citations are not available for this document.

Citations

Downloads

Views